From man to mouse and back again: Advances in defining tumor AKTivities in vivo

DMM Disease Models and Mechanisms

Volumn 3, Issue 11-12, 2010, Pages 705-720

  Restuccia, David F ^a   Hemmings, Brian A ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; DOXORUBICIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INVASION; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL SURVIVAL; DISEASE COURSE; ENZYME ACTIVATION; EXPERIMENTAL MOUSE; GENE MUTATION; HUMAN; IN VIVO STUDY; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 78649311707     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.004671     Document Type: Review

References (234)

1. Abdulkadir, S. A., Magee, J. A., Peters, T. J., Kaleem, Z., Naughton, C. K., Humphrey, P. A. and Milbrandt, J. (2002). Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22, 1495-1503.
2. Alessi, D. R. (2001). Discovery of PDK1, one of the missing links in insulin signal transduction. Colworth Medal Lecture. Biochem. Soc. Trans. 29, 1-14.
3. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B. and Cohen, P. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7, 261-269. (Pubitemid 27176852)
4. Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G. et al. (2010a). A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681-693.
5. Alimonti, A., Carracedo, A., Clohessy, J. G., Trotman, L. C., Nardella, C., Egia, A., Salmena, L., Sampieri, K., Haveman, W. J., Brogi, E. et al. (2010b). Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 42, 454-458.
6. Alliouachene, S., Tuttle, R. L., Boumard, S., Lapointe, T., Berissi, S., Germain, S., Jaubert, F., Tosh, D., Birnbaum, M. J. and Pende, M. (2008). Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. J. Clin. Invest. 118, 3629-3638.
7. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N. and Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554.
8. Altomare, D. A. and Testa, J. R. (2005). Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464.
9. Anisimov, V. N., Egormin, P. A., Bershtein, L. M., Zabezhinskii, M. A., Piskunova, T. S., Popovich, I. G. and Semenchenko, A. V. (2005). Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull. Exp. Biol. Med. 139, 721-723.
10. Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M. and Knight, Z. A. (2008). Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699.
11. Araki, E., Lipes, M. A., Patti, M. E., Bruning, J. C., Haag, B., 3rd, Johnson, R. S. and Kahn, C. R. (1994). Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372, 186-190.
12. Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C. et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772-775. (Pubitemid 41351083)
13. Baeza, N., Weller, M., Yonekawa, Y., Kleihues, P. and Ohgaki, H. (2003). PTEN methylation and expression in glioblastomas. Acta Neuropathol. 106, 479-485.
14. Bai, F., Pei, X. H., Pandolfi, P. P. and Xiong, Y. (2006). p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. Mol. Cell. Biol. 26, 4564-4576.
15. Bayascas, J. R., Leslie, N. R., Parsons, R., Fleming, S. and Alessi, D. R. (2005). Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr. Biol. 15, 1839-1846.
16. Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V. et al. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280-285.
17. Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y. and Bost, F. (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586.
18. Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M. et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402. (Pubitemid 47539306)
19. Bethel, C. R., Faith, D., Li, X., Guan, B., Hicks, J. L., Lan, F., Jenkins, R. B., Bieberich, C. J. and De Marzo, A. M. (2006). Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 66, 10683-10690.
20. Blanco-Aparicio, C., Perez-Gallego, L., Pequeno, B., Leal, J. F., Renner, O. and Carnero, A. (2007). Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 28, 584-594.
21. Boughdady, I. S., Kinsella, A. R., Haboubi, N. Y. and Schofield, P. F. (1992). K-ras gene mutations in adenomas and carcinomas of the colon. Surg. Oncol. 1, 275-282.
22. Bozulic, L. and Hemmings, B. A. (2009). PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr. Opin. Cell Biol. 21, 256-261.
23. Brachmann, S., Fritsch, C., Maira, S. M. and Garcia-Echeverria, C. (2009). PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr. Opin. Cell Biol. 21, 194-198.
24. Brazil, D. P. and Hemmings, B. A. (2001). Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 26, 657-664.
25. Burmer, G. C., Rabinovitch, P. S. and Loeb, L. A. (1991). Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ. Health Perspect. 93, 27-31.
26. Buttitta, F., Felicioni, L., Barassi, F., Martella, C., Paolizzi, D., Fresu, G., Salvatore, S., Cuccurullo, F., Mezzetti, A., Campani, D. et al. (2006). PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J. Pathol. 208, 350-355.
27. Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B. and Thompson, C. B. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752.
28. Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S., Cristiano, B. E., Pearson, R. B. and Phillips, W. A. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681.
29. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S. et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439-444. (Pubitemid 47123510)
30. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C. et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074.
31. Carter, B. S., Ewing, C. M., Ward, W. S., Treiger, B. F., Aalders, T. W., Schalken, J. A., Epstein, J. I. and Isaacs, W. B. (1990). Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. USA 87, 8751-8755.
32. Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T. et al. (2009). Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624.
33. Casimiro, M., Rodriguez, O., Pootrakul, L., Aventian, M., Lushina, N., Cromelin, C., Ferzli, G., Johnson, K., Fricke, S., Diba, F. et al. (2007). ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res. 67, 4364-4372.
34. CGARN (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
35. Chen, M. L., Xu, P. Z., Peng, X. D., Chen, W. S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P. P. and Hay, N. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20, 1569-1574.
36. Chen, W. S., Xu, P. Z., Gottlob, K., Chen, M. L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K. et al. (2001). Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203-2208. (Pubitemid 32843832)
37. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H. K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W. et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730.
38. Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N. and Testa, J. R. (1992). AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 89, 9267-9271.
39. Cheung, M., Sharma, A., Madhunapantula, S. V. and Robertson, G. P. (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68, 3429-3439.
40. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. and Birnbaum, M. J. (2001a). Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349-38352. (Pubitemid 33660170)
41. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., 3rd, Kaestner, K. H., Bartolomei, M. S., Shulman, G. I. and Birnbaum, M. J. (2001b). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292, 1728-1731.
42. Cho, N. Y., Choi, M., Kim, B. H., Cho, Y. M., Moon, K. C. and Kang, G. H. (2006). BRAF and KRAS mutations in prostatic adenocarcinoma. Int. J. Cancer 119, 1858-1862.
43. Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D. et al. (2008). Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5, e8.
44. Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S., Gaudin, P., Fazzari, M., Zhang, Z., Massague, J. et al. (1998). Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. 90, 1284-1291. (Pubitemid 28433473)
45. Crino, P. B., Nathanson, K. L. and Henske, E. P. (2006). The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345-1356.
46. Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky, W. E., Jr, You, M. J., DePinho, R. A., McMahon, M. and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
47. Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J., Gershenwald, J. E. and Mills, G. B. (2008). A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99, 1265-1268.
48. Dearth, R. K., Cui, X., Kim, H. J., Kuiatse, I., Lawrence, N. A., Zhang, X., Divisova, J., Britton, O. L., Mohsin, S., Allred, D. C. et al. (2006). Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol. Cell. Biol. 26, 9302-9314.
49. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. and Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355.
50. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C. and Pandolfi, P. P. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27, 222-224. (Pubitemid 32157454)
51. Dickson, M. A. and Schwartz, G. K. (2009). Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 16, 36-43.
52. Dourdin, N., Schade, B., Lesurf, R., Hallett, M., Munn, R. J., Cardiff, R. D. and Muller, W. J. (2008). Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res. 68, 2122-2131.
53. Easton, R. M., Cho, H., Roovers, K., Shineman, D. W., Mizrahi, M., Forman, M. S., Lee, V. M., Szabolcs, M., de Jong, R., Oltersdorf, T. et al. (2005). Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol. Cell. Biol. 25, 1869-1878.
54. Eng, C. (2003). PTEN: one gene, many syndromes. Hum. Mutat. 22, 183-198.
55. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y. et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356.
56. Feilotter, H. E., Nagai, M. A., Boag, A. H., Eng, C. and Mulligan, L. M. (1998). Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16, 1743-1748.
57. Feng, J., Park, J., Cron, P., Hess, D. and Hemmings, B. A. (2004). Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 279, 41189-41196.
58. Fernandez, P. L., Arce, Y., Farre, X., Martinez, A., Nadal, A., Rey, M. J., Peiro, N., Campo, E. and Cardesa, A. (1999). Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J. Pathol. 187, 563-566.
59. Fernandez-Marcos, P. J., Abu-Baker, S., Joshi, J., Galvez, A., Castilla, E. A., Canamero, M., Collado, M., Saez, C., Moreno-Bueno, G., Palacios, J. et al. (2009). Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. Proc. Natl. Acad. Sci. USA 106, 12962-12967.
60. Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A. et al. (2008). The identification of 2- (1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-ylthieno[ 3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522-5532.
61. Forbes, S. A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C. Y., Jia, M., Ewing, R., Menzies, A. et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652-D657.
62. Furusato, B., Gao, C. L., Ravindranath, L., Chen, Y., Cullen, J., McLeod, D. G., Dobi, A., Srivastava, S., Petrovics, G. and Sesterhenn, I. A. (2008). Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod. Pathol. 21, 67-75.
63. Gallia, G. L., Rand, V., Siu, I. M., Eberhart, C. G., James, C. D., Marie, S. K., Oba- Shinjo, S. M., Carlotti, C. G., Caballero, O. L., Simpson, A. J. et al. (2006). PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol. Cancer Res. 4, 709-714. (Pubitemid 44683311)
64. Gao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M. and Abate-Shen, C. (2006). Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc. Natl. Acad. Sci. USA 103, 14477-14482.
65. Garcia, J. M., Silva, J., Pena, C., Garcia, V., Rodriguez, R., Cruz, M. A., Cantos, B., Provencio, M., Espana, P. and Bonilla, F. (2004). Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41, 117-124.
66. Gary, B., Azuero, R., Mohanty, G. S., Bell, W. C., Eltoum, I. E. and Abdulkadir, S. A. (2004). Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am. J. Pathol. 164, 1607-1614.
67. Gnanapragasam, V. J., Robinson, M. C., Marsh, C., Robson, C. N., Hamdy, F. C. and Leung, H. Y. (2003). FGF8 isoform b expression in human prostate cancer. Br. J. Cancer 88, 1432-1438.
68. Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P. and Witte, O. N. (2010). Identification of a cell of origin for human prostate cancer. Science 329, 568-571.
69. Gray, I. C., Phillips, S. M., Lee, S. J., Neoptolemos, J. P., Weissenbach, J. and Spurr, N. K. (1995). Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 55, 4800-4803.
70. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J. and Sabatini, D. M. (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11, 859-871.
71. Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H. and Sabatini, D. M. (2009). mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148-159.
72. Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K. and Downward, J. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129, 957-968. (Pubitemid 46802703)
73. Guy, C. T., Cardiff, R. D. and Muller, W. J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961.
74. Hadad, S. M., Baker, L., Quinlan, P. R., Robertson, K. E., Bray, S. E., Thomson, G., Kellock, D., Jordan, L. B., Purdie, C. A., Hardie, D. G. et al. (2009). Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9, 307.
75. Hartmann, C., Bartels, G., Gehlhaar, C., Holtkamp, N. and von Deimling, A. (2005). PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol. 109, 639-642.
76. Hashimoto, K., Mori, N., Tamesa, T., Okada, T., Kawauchi, S., Oga, A., Furuya, T., Tangoku, A., Oka, M. and Sasaki, K. (2004). Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod. Pathol. 17, 617-622.
77. Hausherr, C. K., Schiffer, I. B., Gebhard, S., Banic, A., Tanner, B., Kolbl, H., Thoenes, E., Beckers, T., Spangenberg, C., Prawitt, D. et al. (2006). Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model. Mol. Carcinog. 45, 302-308. (Pubitemid 43749197)
78. Herbst, R. A., Weiss, J., Ehnis, A., Cavenee, W. K. and Arden, K. C. (1994). Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res. 54, 3111-3114.
79. Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. and Struhl, K. (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507-7511.
80. Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E. and Fuller, G. N. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25, 55-57.
81. Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M. and Ruggero, D. (2010). Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17, 249-261.
82. Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H. et al. (2006). A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66, 3987-3991.
83. Huynh, H. (2010). AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 116, 1315-1325.
84. Ichimura, K., Vogazianou, A. P., Liu, L., Pearson, D. M., Backlund, L. M., Plant, K., Baird, K., Langford, C. F., Gregory, S. G. and Collins, V. P. (2008). 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27, 2097-2108. (Pubitemid 351442746)
85. Inoki, K., Zhu, T. and Guan, K. L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590.
86. Inoue-Narita, T., Hamada, K., Sasaki, T., Hatakeyama, S., Fujita, S., Kawahara, K., Sasaki, M., Kishimoto, H., Eguchi, S., Kojima, I. et al. (2008). Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res. 68, 5760-5768.
87. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137.
88. Jaggi, M., Johansson, S. L., Baker, J. J., Smith, L. M., Galich, A. and Balaji, K. C. (2005). Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol. Oncol. 23, 402-406.
89. Jenkins, R. B., Qian, J., Lieber, M. M. and Bostwick, D. G. (1997). Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57, 524-531.
90. Jhappan, C., Morse, H. C., 3rd, Fleischmann, R. D., Gottesman, M. M. and Merlino, G. (1997). DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. Nat. Genet. 17, 483-486.
91. Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M. et al. (2008). Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776-779.
92. Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A. and Jacks, T. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116. (Pubitemid 32391044)
93. Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S., Zhou, J., Turner, J., Lisanti, M. P., Russell, R. G. et al. (2007). Akt1 governs breast cancer progression in vivo. Proc. Natl. Acad. Sci. USA 104, 7438-7443.
94. Kalender, A., Selvaraj, A., Kim, S.-Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J. et al. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner. Cell Metab. 11, 390-401.
95. Khan, S., Kumagai, T., Vora, J., Bose, N., Sehgal, I., Koeffler, P. H. and Bose, S. (2004). PTEN promoter is methylated in a proportion of invasive breast cancers. Int. J. Cancer 112, 407-410.
96. Kim, M. J., Cardiff, R. D., Desai, N., Banach-Petrosky, W. A., Parsons, R., Shen, M. M. and Abate-Shen, C. (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99, 2884-2889. (Pubitemid 34240555)
97. Kim, M. S., Jeong, E. G., Yoo, N. J. and Lee, S. H. (2008). Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer 98, 1533-1535.
98. King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S. et al. (2009). Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526.
99. Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C. et al. (2008). Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118, 3051-3064.
100. Klein, S. and Levitzki, A. (2009). Targeting the EGFR and the PKB pathway in cancer. Curr. Opin. Cell Biol. 21, 185-193.
101. Klezovitch, O., Risk, M., Coleman, I., Lucas, J. M., Null, M., True, L. D., Nelson, P. S. and Vasioukhin, V. (2008). A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. USA 105, 2105-2110.
102. Knobbe, C. B. and Reifenberger, G. (2003). Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′- kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507-518.
103. Komiya, A., Suzuki, H., Ueda, T., Yatani, R., Emi, M., Ito, H. and Shimazaki, J. (1996). Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer 17, 245-253.
104. Kondo, K., Yao, M., Kobayashi, K., Ota, S., Yoshida, M., Kaneko, S., Baba, M., Sakai, N., Kishida, T., Kawakami, S. et al. (2001). PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int. J. Cancer 91, 219-224. (Pubitemid 32041743)
105. Kremer, C. L., Klein, R. R., Mendelson, J., Browne, W., Samadzedeh, L. K., Vanpatten, K., Highstrom, L., Pestano, G. A. and Nagle, R. B. (2006). Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66, 1203-1212.
106. Kuhn, E. J., Kurnot, R. A., Sesterhenn, I. A., Chang, E. H. and Moul, J. W. (1993). Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol. 150, 1427-1433.
107. Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N. and Ittmann, M. (2001). Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98, 11563-11568.
108. Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J. and Lee, S. H. (2005). PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24, 1477-1480.
109. Lee, J. W., Soung, Y. H., Seo, S. H., Kim, S. Y., Park, C. H., Wang, Y. P., Park, K., Nam, S. W., Park, W. S., Kim, S. H. et al. (2006). Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res. 12, 57-61.
110. Lemoine, N. R., Jain, S., Hughes, C. M., Staddon, S. L., Maillet, B., Hall, P. A. and Kloppel, G. (1992). Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 102, 230-236.
111. Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I. and Boyd, J. (2005). Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11, 2875-2878. (Pubitemid 40525186)
112. Li, B., Sun, A., Youn, H., Hong, Y., Terranova, P. F., Thrasher, J. B., Xu, P. and Spencer, D. (2007). Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 28, 572-583.
113. Lin, H.-K., Chen, Z., Wang, G., Nardella, C., Lee, S.-W., Chan, C.-H., Yang, W.-L., Wang, J., Egia, A., Nakayama, K. I. et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379.
114. Liu, J., Weiss, H. L., Rychahou, P., Jackson, L. N., Evers, B. M. and Gao, T. (2009). Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 28, 994-1004.
115. Liu, T. J., Koul, D., LaFortune, T., Tiao, N., Shen, R. J., Maira, S. M., Garcia-Echevrria, C. and Yung, W. K. (2009). NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther. 8, 2204-2210.
116. LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. and Dennis, P. A. (2008). Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32-50.
117. Luo, J., Sobkiw, C. L., Logsdon, N. M., Watt, J. M., Signoretti, S., O'Connell, F., Shin, E., Shim, Y., Pao, L., Neel, B. G. et al. (2005). Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 102, 10238-10243. (Pubitemid 41023356)
118. Ma, L., Teruya-Feldstein, J., Behrendt, N., Chen, Z., Noda, T., Hino, O., Cordon-Cardo, C. and Pandolfi, P. P. (2005). Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19, 1779-1786.
119. Ma, Z., Gibson, S. L., Byrne, M. A., Zhang, J., White, M. F. and Shaw, L. M. (2006). Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol. Cell. Biol. 26, 9338-9351.
120. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chene, P., De Pover, A., Schoemaker, K. et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863.
121. Maira, S. M., Stauffer, F., Schnell, C. and Garcia-Echeverria, C. (2009). PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans. 37, 265-272.
122. Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q., Bikoff, R., Ma, H., Kantoff, P. W., Golub, T. R. et al. (2003). Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. USA 100, 7841-7846.
123. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R. et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601. (Pubitemid 38796850)
124. Majumder, P. K., Grisanzio, C., O'Connell, F., Barry, M., Brito, J. M., Xu, Q., Guney, I., Berger, R., Herman, P., Bikoff, R. et al. (2008). A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14, 146-155.
125. Mak, B. C., Kenerson, H. L., Aicher, L. D., Barnes, E. A. and Yeung, R. S. (2005). Aberrant {beta}-catenin signaling in tuberous sclerosis. Am. J. Pathol. 167, 107-116.
126. Malanga, D., Scrima, M., De Marco, C., Fabiani, F., De Rosa, N., De Gisi, S., Malara, N., Savino, R., Rocco, G., Chiappetta, G. et al. (2008). Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7, 665-669.
127. Malik, S. N., Brattain, M., Ghosh, P. M., Troyer, D. A., Prihoda, T., Bedolla, R. and Kreisberg, J. I. (2002). Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 8, 1168-1171.
128. Malstrom, S., Tili, E., Kappes, D., Ceci, J. D. and Tsichlis, P. N. (2001). Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc. Natl. Acad. Sci. USA 98, 14967-14972.
129. Manning, B. D. and Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
130. Maroulakou, I. G., Oemler, W., Naber, S. P. and Tsichlis, P. N. (2007). Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 67, 167-177.
131. Marx, A. H., Tharun, L., Muth, J., Dancau, A. M., Simon, R., Yekebas, E., Kaifi, J. T., Mirlacher, M., Brummendorf, T. H., Bokemeyer, C. et al. (2009). HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 40, 769-777.
132. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M. and Sellers, W. R. (1999). Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59, 4291-4296.
133. Mende, I., Malstrom, S., Tsichlis, P. N., Vogt, P. K. and Aoki, M. (2001). Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 20, 4419-4423. (Pubitemid 32726886)
134. Milam, M. R., Celestino, J., Wu, W., Broaddus, R. R., Schmeler, K. M., Slomovitz, B. M., Soliman, P. T., Gershenson, D. M., Wang, H., Ellenson, L. H. et al. (2007). Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am. J. Obst. Gynecol. 196, 247 e241-e245.
135. Milam, M. R., Soliman, P. T., Chung, L. H., Schmeler, K. M., Bassett, R. L., Jr, Broaddus, R. R. and Lu, K. H. (2008). Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. Int. J. Gynecol. Cancer 18, 146-151.
136. Mizoguchi, M., Nutt, C. L., Mohapatra, G. and Louis, D. N. (2004). Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 14, 372-377.
137. Mora, A., Komander, D., van Aalten, D. M. and Alessi, D. R. (2004). PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161-170.
138. Morote, J., de Torres, I., Caceres, C., Vallejo, C., Schwartz, S., Jr and Reventos, J. (1999). Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int. J. Cancer 84, 421-425.
139. Mosley, J. D., Poirier, J. T., Seachrist, D. D., Landis, M. D. and Keri, R. A. (2007). Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor
140. Mounir, Z., Krishnamoorthy, J. L., Robertson, G. P., Scheuner, D., Kaufman, R. J., Georgescu, M. M. and Koromilas, A. E. (2009). Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Sci. Signal. 2, ra85.
141. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
142. Nagle, J. A., Ma, Z., Byrne, M. A., White, M. F. and Shaw, L. M. (2004). Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol. Cell. Biol. 24, 9726-9735.
143. Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T. L. and Shih, I.-M. (2006). Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 5, 779-785. (Pubitemid 44775134)
144. Nakayama, K., Nakayama, N., Jinawath, N., Salani, R., Kurman, R. J., Shih, I.-M. and Wang, T. L. (2007). Amplicon profiles in ovarian serous carcinomas. Int. J. Cancer 120, 2613-2617.
145. Nardella, C., Chen, Z., Salmena, L., Carracedo, A., Alimonti, A., Egia, A., Carver, B., Gerald, W., Cordon-Cardo, C. and Pandolfi, P. P. (2008). Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22, 2172-2177.
146. Nardella, C., Carracedo, A., Alimonti, A., Hobbs, R. M., Clohessy, J. G., Chen, Z., Egia, A., Fornari, A., Fiorentino, M., Loda, M. et al. (2009). Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal. 2, ra2.
147. O'Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L. et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508.
148. Oda, K., Stokoe, D., Taketani, Y. and McCormick, F. (2005). High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65, 10669-10673.
149. Parsons, D. W., Wang, T. L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. et al. (2005). Colorectal cancer: mutations in a signalling pathway. Nature 436, 792.
150. Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L. et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
151. Pearson, H. B., McCarthy, A., Collins, C. M., Ashworth, A. and Clarke, A. R. (2008). Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res. 68, 2223-2232.
152. Pearson, H. B., Phesse, T. J. and Clarke, A. R. (2009). K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 69, 94-101.
153. Pedrero, J. M., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S. and Gonzalez, M. V. (2005). Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114, 242-248.
154. Pei, H., Li, L., Fridley, B. L., Jenkins, G. D., Kalari, K. R., Lingle, W., Petersen, G., Lou, Z. and Wang, L. (2009). FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16, 259-266.
155. Perner, S., Demichelis, F., Beroukhim, R., Schmidt, F. H., Mosquera, J.-M., Setlur, S., Tchinda, J., Tomlins, S. A., Hofer, M. D., Pienta, K. G. et al. (2006). TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341. (Pubitemid 44449140)
156. Petrovics, G., Liu, A., Shaheduzzaman, S., Furusato, B., Sun, C., Chen, Y., Nau, M., Ravindranath, L., Chen, Y., Dobi, A. et al. (2005). Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847-3852.
157. Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., Thomas, R. J. and Phillips, W. A. (2001). The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426-7429.
158. Phoenix, K. N., Vumbaca, F. and Claffey, K. P. (2009). Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat. 113, 101-111.
159. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E. and Parsons, R. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96, 1563-1568.
160. Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M. S., Hobbs, R. M., Sportoletti, P., Varmeh, S., Egia, A., Fedele, G. et al. (2010). Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 3, ra29.
161. Pollizzi, K., Malinowska-Kolodziej, I., Doughty, C., Betz, C., Ma, J., Goto, J. and Kwiatkowski, D. J. (2009). A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles. Hum. Mol. Genet. 18, 2378-2387.
162. Qian, J., Hirasawa, K., Bostwick, D. G., Bergstralh, E. J., Slezak, J. M., Anderl, K. L., Borell, T. J., Lieber, M. M. and Jenkins, R. B. (2002). Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod. Pathol. 15, 35-44.
163. Rasheed, B. K., Stenzel, T. T., McLendon, R. E., Parsons, R., Friedman, A. H., Friedman, H. S., Bigner, D. D. and Bigner, S. H. (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 57, 4187-4190.
164. Rathmell, J. C., Elstrom, R. L., Cinalli, R. M. and Thompson, C. B. (2003). Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol. 33, 2223-2232.
165. Ratnacaram, C. K., Teletin, M., Jiang, M., Meng, X., Chambon, P. and Metzger, D. (2008). Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 105, 2521-2526. (Pubitemid 351520546)
166. Reichelt, U., Duesedau, P., Tsourlakis, M., Quaas, A., Link, B. C., Schurr, P. G., Kaifi, J. T., Gros, S. J., Yekebas, E. F., Marx, A. et al. (2007). Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod. Pathol. 20, 120-129.
167. Renner, O., Fominaya, J., Alonso, S., Blanco-Aparicio, C., Leal, J. F. and Carnero, A. (2007). Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis 28, 1418-1425.
168. Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S. Y., Robell, K. et al. (2008). Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366-2374. (Pubitemid 351521811)
169. Robertson, G. P., Furnari, F. B., Miele, M. E., Glendening, M. J., Welch, D. R., Fountain, J. W., Lugo, T. G., Huang, H. J. and Cavenee, W. K. (1998). In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl. Acad. Sci. USA 95, 9418-9423.
170. Robinson, J. P., VanBrocklin, M. W., Guilbeault, A. R., Signorelli, D. L., Brandner, S. and Holmen, S. L. (2010). Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 29, 335-344.
171. Rodenhuis, S. and Slebos, R. J. (1992). Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 52, 2665s-2669s.
172. Rodriguez, O. C., Lai, E. W., Vissapragada, S., Cromelin, C., Avetian, M., Salinas, P., Ramos, H., Kallakury, B., Casimiro, M., Lisanti, M. P. et al. (2009). A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am. J. Pathol. 174, 2051-2060.
173. Ross, J. S., Nazeer, T., Church, K., Amato, C., Figge, H., Rifkin, M. D. and Fisher, H. A. (1993). Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72, 3020-3028.
174. Rostad, K., Mannelqvist, M., Halvorsen, O. J., Oyan, A. M., Bo, T. H., Stordrange, L., Olsen, S., Haukaas, S. A., Lin, B., Hood, L. et al. (2007). ERG upregulation and related ETS transcription factors in prostate cancer. Int. J. Oncol. 30, 19-32.
175. Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q. and Testa, J. R. (1998). Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81-86.
176. Salvesen, H. B., MacDonald, N., Ryan, A., Jacobs, I. J., Lynch, E. D., Akslen, L. A. and Das, S. (2001). PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 91, 22-26.
177. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J. et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554. (Pubitemid 38541907)
178. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
179. Schmitz, M., Grignard, G., Margue, C., Dippel, W., Capesius, C., Mossong, J., Nathan, M., Giacchi, S., Scheiden, R. and Kieffer, N. (2007). Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int. J. Cancer 120, 1284-1292.
180. Segrelles, C., Lu, J., Hammann, B., Santos, M., Moral, M., Cascallana, J. L., Lara, M. F., Rho, O., Carbajal, S., Traag, J. et al. (2007). Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. Cancer Res. 67, 10879-10888. (Pubitemid 350145917)
181. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S. et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022-8030.
182. Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C. L., Vera, D. R. and Shaw, R. J. (2009). mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 106, 11137-11142.
183. Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B. and Gray, J. W. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99-102.
184. Shi, Y., Yan, H., Frost, P., Gera, J. and Lichtenstein, A. (2005). Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4, 1533-1540.
185. Shim, E.-H., Johnson, L., Noh, H.-L., Kim, Y.-J., Sun, H., Zeiss, C. and Zhang, H. (2003). Expression of the F-Box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res. 63, 1583-1588.
186. Shiota, C., Woo, J. T., Lindner, J., Shelton, K. D. and Magnuson, M. A. (2006). Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583-589.
187. Shoji, K., Oda, K., Nakagawa, S., Hosokawa, S., Nagae, G., Uehara, Y., Sone, K., Miyamoto, Y., Hiraike, H., Hiraike-Wada, O. et al. (2009). The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br. J. Cancer 101, 145-148.
188. Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L. et al. (2000). Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92, 1918-1925. (Pubitemid 32036922)
189. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
190. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
191. Smit, V. T., Boot, A. J., Smits, A. M., Fleuren, G. J., Cornelisse, C. J. and Bos, J. L. (1988). KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16, 7773-7782.
192. Snijders, A. M., Nowee, M. E., Fridlyand, J., Piek, J. M., Dorsman, J. C., Jain, A. N., Pinkel, D., van Diest, P. J., Verheijen, R. H. and Albertson, D. G. (2003). Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 22, 4281-4286.
193. Song, H., Zhang, B., Watson, M. A., Humphrey, P. A., Lim, H. and Milbrandt, J. (2009). Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 28, 3307-3319.
194. Soung, Y. H., Lee, J. W., Nam, S. W., Lee, J. Y., Yoo, N. J. and Lee, S. H. (2006). Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 70, 285-289.
195. Staal, S. P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 84, 5034-5037.
196. Stahl, J. M., Cheung, M., Sharma, A., Trivedi, N. R., Shanmugam, S. and Robertson, G. P. (2003). Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63, 2881-2890.
197. Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L. and Robertson, G. P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010. (Pubitemid 39331010)
198. Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A. et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526.
199. Surucu, B., Bozulic, L., Hynx, D., Parcellier, A. and Hemmings, B. A. (2008). In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J. Biol. Chem. 283, 30025-30033.
200. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W. et al. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169-1178.
201. Suzuki, Y., Orita, M., Shiraishi, M., Hayashi, K. and Sekiya, T. (1990). Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 5, 1037-1043. (Pubitemid 20220246)
202. Szabolcs, M., Keniry, M., Simpson, L., Reid, L. J., Koujak, S., Schiff, S. C., Davidian, G., Licata, S., Gruvberger-Saal, S., Murty, V. V. et al. (2009). Irs2 inactivation suppresses tumor progression in Pten+/- mice. Am. J. Pathol. 174, 276-286.
203. Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S. et al. (1994). Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372, 182-186.
204. Tashiro, H., Blazes, M. S., Wu, R., Cho, K. R., Bose, S., Wang, S. I., Li, J., Parsons, R. and Ellenson, L. H. (1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57, 3935-3940.
205. Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B. et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
206. Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M. and Gray, N. S. (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032.
207. Thuret, R., Chantrel-Groussard, K., Azzouzi, A. R., Villette, J. M., Guimard, S., Teillac, P., Berthon, P., Houlgatte, A., Latil, A. and Cussenot, O. (2005). Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. Br. J. Cancer 92, 236-240.
208. Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B. et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188. (Pubitemid 351240884)
209. Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Van Dyke, T. et al. (2003). Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59.
210. Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H. et al. (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128, 141-156.
211. Tschopp, O., Yang, Z. Z., Brodbeck, D., Dummler, B. A., Hemmings-Mieszczak, M., Watanabe, T., Michaelis, T., Frahm, J. and Hemmings, B. A. (2005). Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132, 2943-2954.
212. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H. K., Debruyne, F. M. J. and Isaacs, W. B. (1992). Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52, 5104-5109.
213. Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y. et al. (2009). AKTindependent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21-32.
214. Vazquez-Martin, A., Oliveras-Ferraros, C. and Menendez, J. A. (2009). The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8, 88-96.
215. Velasco, A., Bussaglia, E., Pallares, J., Dolcet, X., Llobet, D., Encinas, M., Llecha, N., Palacios, J., Prat, J. and Matias-Guiu, X. (2006). PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum. Pathol. 37, 1465-1472. (Pubitemid 44584324)
216. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M. et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726.
217. von Knobloch, R., Konrad, L., Barth, P. J., Brandt, H., Wille, S., Heidenreich, A., Moll, R. and Hofmann, R. (2004). Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin. Cancer Res. 10, 1064-1073. (Pubitemid 38198908)
218. Wang, H., Karikomi, M., Naidu, S., Rajmohan, R., Caserta, E., Chen, H. Z., Rawahneh, M., Moffitt, J., Stephens, J. A., Fernandez, S. A. et al. (2010). Allele-specific tumor spectrum in pten knockin mice. Proc. Natl. Acad. Sci. USA 107, 5142-5147.
219. Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S. et al. (2003). Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221.
220. Wiencke, J. K., Zheng, S., Jelluma, N., Tihan, T., Vandenberg, S., Tamguney, T., Baumber, R., Parsons, R., Lamborn, K. R., Berger, M. S. et al. (2007). Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro-oncology 9, 271-279. (Pubitemid 47169659)
221. Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I. et al. (1998). Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904.
222. Wu, G., Xing, M., Mambo, E., Huang, X., Liu, J., Guo, Z., Chatterjee, A., Goldenberg, D., Gollin, S. M., Sukumar, S. et al. (2005). Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7, R609-R616.
223. Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., Soh, J., Suzuki, M., Wistuba, II, Fong, K. M. et al. (2008). PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68, 6913-6921.
224. Yang, G., Ayala, G., De Marzo, A., Tian, W., Frolov, A., Wheeler, T. M., Thompson, T. C. and Harper, J. W. (2002). Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. 8, 3419-3426.
225. Young, C. D., Nolte, E. C., Lewis, A., Serkova, N. J. and Anderson, S. M. (2008). Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res. 10, R70.
226. Yu, J., Mani, R. S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., Gong, Y. et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454.
227. Yu, W., Kanaan, Y., Baed, Y. K. and Gabrielson, E. (2009). Chromosomal changes in aggressive breast cancers with basal-like features. Cancer. Genet. Cytogenet. 193, 29-37.
228. Zhao, L. and Vogt, P. K. (2010). Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (PI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9, 596-600.
229. Zheng, B., Jeong, J. H., Asara, J. M., Yuan, Y.-Y., Granter, S. R., Chin, L. and Cantley, L. C. (2009). Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33, 237-247.
230. Zhong, C., Saribekyan, G., Liao, C. P., Cohen, M. B. and Roy-Burman, P. (2006). Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res. 66, 2188-2194. (Pubitemid 43294929)
231. Zhou, X. P., Li, Y. J., Hoang-Xuan, K., Laurent-Puig, P., Mokhtari, K., Longy, M., Sanson, M., Delattre, J. Y., Thomas, G. and Hamelin, R. (1999). Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer 84, 150-154.
232. Zhou, X. P., Waite, K. A., Pilarski, R., Hampel, H., Fernandez, M. J., Bos, C., Dasouki, M., Feldman, G. L., Greenberg, L. A., Ivanovich, J. et al. (2003). Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley- Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am. J. Hum. Genet. 73, 404-411.
233. Zhu, Q., Youn, H., Tang, J., Tawfik, O., Dennis, K., Terranova, P. F., Du, J., Raynal, P., Thrasher, J. B. and Li, B. (2008). Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27, 4569-4579.
234. Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A. and Witte, O. N. (2009). ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl. Acad. Sci. USA 106, 12465-12470.